| Literature DB >> 36238163 |
Xuping Xie1, Yan Wang1,2, Nan Sheng1, Shuangquan Zhang1, Yangkun Cao2, Yuan Fu3.
Abstract
MicroRNAs (miRNAs) play an important role in various biological processes and their abnormal expression could lead to the occurrence of diseases. Exploring the potential relationships between miRNAs and diseases can contribute to the diagnosis and treatment of complex diseases. The increasing databases storing miRNA and disease information provide opportunities to develop computational methods for discovering unobserved disease-related miRNAs, but there are still some challenges in how to effectively learn and fuse information from multi-source data. In this study, we propose a multi-view information fusion based method for miRNA-disease association (MDA)prediction, named MVIFMDA. Firstly, multiple heterogeneous networks are constructed by combining the known MDAs and different similarities of miRNAs and diseases based on multi-source information. Secondly, the topology features of miRNAs and diseases are obtained by using the graph convolutional network to each heterogeneous network view, respectively. Moreover, we design the attention strategy at the topology representation level to adaptively fuse representations including different structural information. Meanwhile, we learn the attribute representations of miRNAs and diseases from their similarity attribute views with convolutional neural networks, respectively. Finally, the complicated associations between miRNAs and diseases are reconstructed by applying a bilinear decoder to the combined features, which combine topology and attribute representations. Experimental results on the public dataset demonstrate that our proposed model consistently outperforms baseline methods. The case studies further show the ability of the MVIFMDA model for inferring underlying associations between miRNAs and diseases.Entities:
Keywords: convolutional neural networks; deep learning; graph convolutional networks; miRNA-disease associations; multi-view
Year: 2022 PMID: 36238163 PMCID: PMC9552014 DOI: 10.3389/fgene.2022.979815
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.772
FIGURE 1Overview of MVIFMDA. (A) Construction of multiple miRNA-disease heterogeneous networks using known MDAs and the similarities of miRNAs and diseases. (B) Encoding of heterogeneous network views by GCN to extract topology representations, and using topology representation level attention mechanism to adaptively fuse the different topology information. (C) and (D) Encoding of similarity views by CNN to obtain attribute representations of miRNAs and diseases, respectively.
Results of our model and its variant models.
| Metrics ( | MVIFMDA-noTR | MVIFMDA-noAR | MVIFMDA |
|---|---|---|---|
| AUC |
|
|
|
| AUPR |
|
|
|
| accuracy |
|
|
|
| precision |
|
|
|
| recall |
|
|
|
| F1 |
|
|
|
| precision@5% |
|
|
|
| precision@10% |
|
|
|
| recall @5% |
|
|
|
| recall @10% |
|
|
|
The bold values indicate the best values in rows.
FIGURE 2ROC curves and PR curves of MVIFMDA with all comparison methods.
The performance of MVIFMDA with all comparison methods.
| Metrics ( | MDHGI | ABMDA | NIMGSA | NIMCGCN | DANE-MDA | MMGCN | MVIFMDA |
|---|---|---|---|---|---|---|---|
| AUC |
|
|
|
|
|
|
|
| AUPR |
|
|
|
|
|
|
|
| accuracy |
|
|
|
|
|
|
|
| precision |
|
|
|
|
|
|
|
| recall |
|
|
|
|
|
|
|
| F1 |
|
|
|
|
|
|
|
| precision@5% |
|
|
|
|
|
|
|
| precision@10% |
|
|
|
|
|
|
|
| recall @5% |
|
|
|
|
|
|
|
| recall @10% |
|
|
|
|
|
|
|
The bold values indicate the best values in rows.
The statistical results by paired t-test for MVIFMDA and all comparison methods.
| MVIFMDA versus | MDHGI | ABMDA | NIMGSA | NIMCGCN | DANE-MDA | MMGCN |
|---|---|---|---|---|---|---|
|
| 6.7944e-18 | 1.1456e-07 | 6.5493e-14 | 3.5915e-08 | 2.0171e-13 | 9.7205e-09 |
|
| 2.0333e-19 | 1.3929e-10 | 2.5665e-12 | 4.7847e-08 | 1.7074e-13 | 2.6278e-10 |
Top 20 miRNA candidates related to colonic neoplasms.
| Rank | miRNA | Evidence | Rank | miRNA | Evidence |
|---|---|---|---|---|---|
| 1 | hsa-mir-122 | Unconfirmed | 11 | hsa-mir-100 | dbDEMC |
| 2 | hsa-mir-146b | dbDEMC | 12 | hsa-mir-34b | dbDEMC |
| 3 | hsa-mir-182 | dbDEMC | 13 | hsa-mir-149 | dbDEMC |
| 4 | hsa-mir-214 | dbDEMC | 14 | hsa-mir-342 | dbDEMC |
| 5 | hsa-mir-29c | dbDEMC | 15 | hsa-mir-26b | dbDEMC |
| 6 | hsa-mir-27b | dbDEMC | 16 | hsa-mir-196a-2 | Unconfirmed |
| 7 | hsa-mir-206 | dbDEMC | 17 | hsa-mir-193b | dbDEMC |
| 8 | hsa-mir-183 | dbDEMC | 18 | hsa-mir-99a | dbDEMC |
| 9 | hsa-mir-34c | dbDEMC | 19 | hsa-mir-29b-2 | dbDEMC |
| 10 | hsa-mir-144 | dbDEMC | 20 | hsa-mir-494 | dbDEMC |
Top 20 miRNA candidates related to esophageal neoplasms.
| Rank | miRNA | Evidence | Rank | miRNA | Evidence |
|---|---|---|---|---|---|
| 1 | hsa-mir-17 | dbDEMC | 11 | hsa-mir-23a | dbDEMC |
| 2 | hsa-mir-29a | dbDEMC | 12 | hsa-mir-125a | dbDEMC |
| 3 | hsa-mir-222 | dbDEMC | 13 | hsa-mir-15b | dbDEMC |
| 4 | hsa-mir-142 | dbDEMC | 14 | hsa-mir-206 | dbDEMC |
| 5 | hsa-mir-30a | dbDEMC | 15 | hsa-mir-125b-1 | dbDEMC |
| 6 | hsa-mir-132 | dbDEMC | 16 | hsa-mir-23b | dbDEMC |
| 7 | hsa-mir-18a | dbDEMC | 17 | hsa-mir-16-1 | dbDEMC |
| 8 | hsa-mir-200b | dbDEMC | 18 | hsa-let-7d | dbDEMC |
| 9 | hsa-mir-182 | dbDEMC | 19 | hsa-mir-125b-2 | dbDEMC |
| 10 | hsa-mir-19b-1 | dbDEMC | 20 | hsa-mir-107 | dbDEMC |
Top 20 miRNA candidates related to lymphoma.
| Rank | miRNA | Evidence | Rank | miRNA | Evidence |
|---|---|---|---|---|---|
| 1 | hsa-mir-34a | dbDEMC | 11 | hsa-mir-132 | dbDEMC |
| 2 | hsa-mir-223 | dbDEMC | 12 | hsa-mir-23a | dbDEMC |
| 3 | hsa-mir-145 | dbDEMC | 13 | hsa-mir-182 | dbDEMC |
| 4 | hsa-mir-29a | dbDEMC | 14 | hsa-mir-192 | dbDEMC |
| 5 | hsa-mir-30a | dbDEMC | 15 | hsa-mir-214 | dbDEMC |
| 6 | hsa-let-7b | dbDEMC | 16 | hsa-mir-15b | dbDEMC |
| 7 | hsa-mir-195 | dbDEMC | 17 | hsa-mir-183 | dbDEMC |
| 8 | hsa-mir-106b | dbDEMC | 18 | hsa-let-7c | dbDEMC |
| 9 | hsa-mir-146b | dbDEMC | 19 | hsa-mir-130a | dbDEMC |
| 10 | hsa-mir-27a | dbDEMC | 20 | hsa-mir-205 | dbDEMC |
Top 20 miRNA candidates related to breast neoplasms. The miRNAs associated with breast neoplasms are deleted before training the MVIFMDA model.
| Rank | miRNA | Evidence | Rank | miRNA | Evidence |
|---|---|---|---|---|---|
| 1 | hsa-mir-21 | HMDD | 11 | hsa-mir-210 | HMDD |
| 2 | hsa-mir-155 | HMDD | 12 | hsa-mir-221 | HMDD |
| 3 | hsa-mir-146a | HMDD | 13 | hsa-mir-20a | HMDD |
| 4 | hsa-mir-126 | HMDD | 14 | hsa-mir-19a | HMDD |
| 5 | hsa-mir-150 | HMDD | 15 | hsa-mir-146b | HMDD |
| 6 | hsa-mir-223 | HMDD | 16 | hsa-mir-142 | HMDD |
| 7 | hsa-mir-34a | HMDD | 17 | hsa-mir-143 | HMDD |
| 8 | hsa-mir-17 | HMDD | 18 | hsa-mir-122 | HMDD |
| 9 | hsa-mir-145 | HMDD | 19 | hsa-mir-222 | HMDD |
| 10 | hsa-mir-29a | HMDD | 20 | hsa-mir-22 | HMDD |